The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tabalumab Modestly Effective in Systemic Lupus Erythematosus

Tabalumab Modestly Effective in Systemic Lupus Erythematosus

October 7, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Tabalumab, a monoclonal antibody to B-cell activating factor, was modestly better than placebo in relieving symptoms of systemic lupus erythematosus (SLE), according to results from the ILLUMINATE-2 trial.

You Might Also Like
  • Systemic Lupus Erythematosus
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report

“Lupus is a complicated disease that does not behave the same way in all patients who share the clinical symptoms,” Dr. Joan T. Merrill from the University of Oklahoma Health Sciences Center in Oklahoma City told Reuters Health by email. “Developing treatments and figuring out how to optimize patient selection and dosing has proven to be a formidable task.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Merrill’s team investigated the efficacy and safety of tabalumab in a 52-week multicenter, randomized, placebo-controlled trial of 1,124 patients with SLE. Just over three-quarters of the patients completed the trial.

More patients in the group receiving tabalumab 120 mg every two weeks than in the placebo group met the primary endpoint, achieving an SLE Responder Index 5 (SRI-5) improvement at week 52 (38.4% vs. 27.7%, p=0.002). This was not the case for patients in the group receiving tabalumab 120 mg every four weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment and placebo groups did not differ significantly, however, in any of the secondary outcomes—change from baseline in Brief Fatigue Index, time to first severe SLE flare, corticosteroid-sparing effects, and so on.

Treatment-emergent and serious adverse events occurred with similar frequency in the tabalumab and placebo groups, but significantly more tabalumab patients reported depression or suicidal ideation, the researchers reported in Annals of the Rheumatic Diseases, online Sept. 19.

Tabalumab had significant impacts on its immunological targets with decreases in mean total B cells, immunoglobulins and anti-dsDNA (double-strand DNA) antibodies.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Eli Lilly and Company, which funded the trials and employed several of the authors, discontinued development of tabalumab for SLE on the basis of the lackluster efficacy results in this and other phase 3 studies. The company had previously discontinued tabalumab development for rheumatoid arthritis for similar reasons.

“We probably need more carefully designed early phase trials to figure out, at lower cost, whether a treatment works, and if so, for what subset of the population,” Dr. Merrill said. “Then we might be able to put together pivotal Phase III trials that are also more efficient and streamlined, avoiding these enormous-sized, hugely expensive Phase III trial designs altogether.”

“Current trials have been failing because they were designed to allow disparate background medications to be used in disparate subsets of the populations,” Dr. Merrill explained. “This has been considered necessary for patient’s safety, but this is only true for patients with organ-threatening disease. In fact looking at data only in the sicker subset of patients, it is OK to design trials this way, since the severity of the illness means that over-treatment in the background will not blur interpretation of the data.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, SLE (Lupus) Tagged With: B cells, SLE, systemic lupus erythematosus (SLE), tabalumab

You Might Also Like:
  • Systemic Lupus Erythematosus
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report
  • Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)